TQB3473 not checked
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “TQB3473 tablet is a selective Spleen tyrosine kinase (Syk) inhibitor.”In the company’s words, NCT06900920 on ClinicalTrials.gov
- Tested for
- Primary Immune Thrombocytopenia (2 trials)
- Main trialPhase 3
- “This is a randomized, double-blind, placebo-controlled Phase III clinical study designed to demonstrate that TQB3473 tablets significantly improve the sustained response rate compared to placebo in adult patients with chronic ITP who have previously received standard corticosteroid therapy and have failed or relapsed after at least one standard ITP treatment. The study consists of a treatment period and a safety follow-up period.”In the company’s words, NCT06900920 on ClinicalTrials.gov
Other drugs for Primary Immune Thrombocytopenia
- RilzabrutinibSanofi · Phase 3
- Human immunoglobulinGrand Shuyang Life Sciences (Chengdu) Co., Ltd. · Phase 3
- Kedrion IVIG 10%Kedrion S.p.A. · Phase 3
- Efgartigimodargenx · Phase 3
- QL0911Qilu Pharmaceutical · Phase 3
- MezagitamabTakeda · Phase 3
Coming up2
- Mar 2027Phase 3 trial completes · ClinicalTrials.gov
- Sep 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Mar 2027 | A Study of TQB3473 Tablets Compared to Placebo in the Treatment of Adult Primary Immune Thrombocytopenia | |
| Phase 2Not yet recruiting | Sep 2027 | A Study on the Safety and Efficacy of TQB3473 Tablets in the Treatment of Persistent or Chronic Primary Immune Thrombocytopenia (ITP) in Adults | |
| Phase 1Unknown | Dec 2021 | A Study of TQB3473 Tablets in Subjects With Relapsed or Refractory Hematological Malignancies |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026